Skip to main content

Table 2 Point estimates and 95% confidence intervals for OCV efficacy by time of vaccination and risk of culture-confirmed cholera by age at time of risk. Estimates are from the B/T model

From: Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial

 

Full a

Outbreak-free b

 

1-HR (95% CI) c

1-HR (95% CI)

Vaccine efficacy

 ages 1 to <5 years

0.34 (-0.09, 0.60)

0.38 (-0.02, 0.62)

 ages 5 to <15 years

0.71 (0.48, 0.84)

0.85 (0.67, 0.93)

 ages 15 years and older

0.73 (0.58, 0.83)

0.69 (0.49, 0.81)

Participant age

 ages 1 to <5 years (ref)

0

0

 ages 5 to <15 years

0.74 (0.62, 0.83)

0.78 (0.66, 0.86)

 ages 15 years and older years

0.88 (0.82, 0.92)

0.89 (0.83, 0.93)

  1. aall participants were included
  2. bparticipants with events during March–April 2010 were excluded
  3. c1-hazard ratio, which can be interpreted as the protective efficacy for the vaccine effect
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us